vs

Side-by-side financial comparison of EXACT SCIENCES CORP (EXAS) and Atlassian Corp (TEAM). Click either name above to swap in a different company.

Atlassian Corp is the larger business by last-quarter revenue ($1.6B vs $878.4M, roughly 1.8× EXACT SCIENCES CORP). Atlassian Corp runs the higher net margin — -2.7% vs -9.8%, a 7.1% gap on every dollar of revenue. On growth, Atlassian Corp posted the faster year-over-year revenue change (23.3% vs 23.1%). Atlassian Corp produced more free cash flow last quarter ($168.5M vs $120.4M).

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

The Dragoneer Investment Group (Dragoneer) is an American investment firm based in San Francisco, California. The firm focuses on technology investments in both public and private markets globally.

EXAS vs TEAM — Head-to-Head

Bigger by revenue
TEAM
TEAM
1.8× larger
TEAM
$1.6B
$878.4M
EXAS
Growing faster (revenue YoY)
TEAM
TEAM
+0.2% gap
TEAM
23.3%
23.1%
EXAS
Higher net margin
TEAM
TEAM
7.1% more per $
TEAM
-2.7%
-9.8%
EXAS
More free cash flow
TEAM
TEAM
$48.1M more FCF
TEAM
$168.5M
$120.4M
EXAS

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
EXAS
EXAS
TEAM
TEAM
Revenue
$878.4M
$1.6B
Net Profit
$-86.0M
$-42.6M
Gross Margin
70.1%
85.0%
Operating Margin
-9.4%
-3.0%
Net Margin
-9.8%
-2.7%
Revenue YoY
23.1%
23.3%
Net Profit YoY
90.1%
-11.6%
EPS (diluted)
$-0.45
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXAS
EXAS
TEAM
TEAM
Q4 25
$878.4M
$1.6B
Q3 25
$850.7M
$1.4B
Q2 25
$811.1M
$1.4B
Q1 25
$706.8M
$1.4B
Q4 24
$713.4M
$1.3B
Q3 24
$708.7M
$1.2B
Q2 24
$699.3M
Q1 24
$637.5M
$1.2B
Net Profit
EXAS
EXAS
TEAM
TEAM
Q4 25
$-86.0M
$-42.6M
Q3 25
$-19.6M
$-51.9M
Q2 25
$-1.2M
$-23.9M
Q1 25
$-101.2M
$-70.8M
Q4 24
$-864.6M
$-38.2M
Q3 24
$-38.2M
$-123.8M
Q2 24
$-15.8M
Q1 24
$-110.2M
$12.8M
Gross Margin
EXAS
EXAS
TEAM
TEAM
Q4 25
70.1%
85.0%
Q3 25
68.6%
82.0%
Q2 25
69.3%
83.1%
Q1 25
70.8%
83.8%
Q4 24
69.0%
82.7%
Q3 24
69.4%
81.7%
Q2 24
69.8%
Q1 24
70.0%
82.1%
Operating Margin
EXAS
EXAS
TEAM
TEAM
Q4 25
-9.4%
-3.0%
Q3 25
-3.0%
-6.7%
Q2 25
-0.3%
-2.1%
Q1 25
-13.6%
-0.9%
Q4 24
-122.8%
-4.5%
Q3 24
-5.6%
-2.7%
Q2 24
-3.8%
Q1 24
-16.7%
1.5%
Net Margin
EXAS
EXAS
TEAM
TEAM
Q4 25
-9.8%
-2.7%
Q3 25
-2.3%
-3.6%
Q2 25
-0.1%
-1.7%
Q1 25
-14.3%
-5.2%
Q4 24
-121.2%
-3.0%
Q3 24
-5.4%
-10.4%
Q2 24
-2.3%
Q1 24
-17.3%
1.1%
EPS (diluted)
EXAS
EXAS
TEAM
TEAM
Q4 25
$-0.45
$-0.16
Q3 25
$-0.10
$-0.20
Q2 25
$-0.01
$-0.08
Q1 25
$-0.54
$-0.27
Q4 24
$-4.69
$-0.15
Q3 24
$-0.21
$-0.48
Q2 24
$-0.09
Q1 24
$-0.60
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXAS
EXAS
TEAM
TEAM
Cash + ST InvestmentsLiquidity on hand
$964.7M
$1.6B
Total DebtLower is stronger
Stockholders' EquityBook value
$2.4B
$1.6B
Total Assets
$5.9B
$6.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXAS
EXAS
TEAM
TEAM
Q4 25
$964.7M
$1.6B
Q3 25
$1.0B
$2.8B
Q2 25
$858.4M
$2.9B
Q1 25
$786.2M
$3.0B
Q4 24
$1.0B
$2.5B
Q3 24
$1.0B
$2.2B
Q2 24
$946.8M
Q1 24
$652.1M
$2.1B
Stockholders' Equity
EXAS
EXAS
TEAM
TEAM
Q4 25
$2.4B
$1.6B
Q3 25
$2.5B
$1.4B
Q2 25
$2.5B
$1.3B
Q1 25
$2.4B
$1.4B
Q4 24
$2.4B
$1.2B
Q3 24
$3.2B
$1.0B
Q2 24
$3.2B
Q1 24
$3.1B
$1.1B
Total Assets
EXAS
EXAS
TEAM
TEAM
Q4 25
$5.9B
$6.2B
Q3 25
$5.9B
$5.7B
Q2 25
$5.8B
$6.0B
Q1 25
$5.7B
$5.9B
Q4 24
$5.9B
$5.4B
Q3 24
$6.7B
$5.0B
Q2 24
$6.7B
Q1 24
$6.4B
$5.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXAS
EXAS
TEAM
TEAM
Operating Cash FlowLast quarter
$151.7M
$177.8M
Free Cash FlowOCF − Capex
$120.4M
$168.5M
FCF MarginFCF / Revenue
13.7%
10.6%
Capex IntensityCapex / Revenue
3.6%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$356.8M
$1.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXAS
EXAS
TEAM
TEAM
Q4 25
$151.7M
$177.8M
Q3 25
$219.9M
$128.7M
Q2 25
$89.0M
$375.3M
Q1 25
$30.8M
$652.7M
Q4 24
$47.1M
$351.9M
Q3 24
$138.7M
$80.5M
Q2 24
$107.1M
Q1 24
$-82.3M
$565.4M
Free Cash Flow
EXAS
EXAS
TEAM
TEAM
Q4 25
$120.4M
$168.5M
Q3 25
$190.0M
$114.6M
Q2 25
$46.7M
$360.3M
Q1 25
$-365.0K
$638.3M
Q4 24
$10.7M
$342.6M
Q3 24
$112.6M
$74.3M
Q2 24
$71.2M
Q1 24
$-120.0M
$554.9M
FCF Margin
EXAS
EXAS
TEAM
TEAM
Q4 25
13.7%
10.6%
Q3 25
22.3%
8.0%
Q2 25
5.8%
26.0%
Q1 25
-0.1%
47.0%
Q4 24
1.5%
26.6%
Q3 24
15.9%
6.3%
Q2 24
10.2%
Q1 24
-18.8%
46.7%
Capex Intensity
EXAS
EXAS
TEAM
TEAM
Q4 25
3.6%
0.6%
Q3 25
3.5%
1.0%
Q2 25
5.2%
1.1%
Q1 25
4.4%
1.1%
Q4 24
5.1%
0.7%
Q3 24
3.7%
0.5%
Q2 24
5.1%
Q1 24
5.9%
0.9%
Cash Conversion
EXAS
EXAS
TEAM
TEAM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
44.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

TEAM
TEAM

Cloud Deployment Services$1.1B67%
Data Center Deployment$435.6M27%
Marketplace And Services Deployment$83.7M5%

Related Comparisons